Levosimendan
Names
[ CAS No. ]:
141505-33-1
[ Name ]:
Levosimendan
[Synonym ]:
Levosimedan
Mesoxalonitrile (-)-[p-[(R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl]phenyl]hydrazone
({4-[(4R)-4-Methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl]phenyl}hydrazono)malononitrile
({4-[(4R)-4-Methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridazinyl]phenyl}hydrazono)malononitrile
(R)-[[4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile
Propanedinitrile, 2-[2-[4-[(4R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl]phenyl]hydrazinylidene]-
Levosimendan
(R)-(-)-2-[4-(4-methyl-6-oxo-1,4,5,6,-tetrahydropyridazin-3-yl)phenylhydrazono]propanedinitrile
MFCD00867135
Simdax
(2-{4-[(4R)-4-Methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl]phenyl}hydrazinyliden)propandinitril
2-[[4-[(4R)-4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl]phenyl]hydrazinylidene]propanedinitrile
(R)-Simendan
Biological Activity
[Description]:
[Related Catalog]:
[References]
[Related Small Molecules]
Chemical & Physical Properties
[ Density]:
1.3±0.1 g/cm3
[ Melting Point ]:
216-219ºC (dec.)
[ Molecular Formula ]:
C14H12N6O
[ Molecular Weight ]:
280.285
[ Exact Mass ]:
280.107269
[ PSA ]:
113.43000
[ LogP ]:
0.59
[ Index of Refraction ]:
1.673
Safety Information
[ Symbol ]:
GHS07
[ Signal Word ]:
Warning
[ Hazard Statements ]:
H302-H312-H332
[ Precautionary Statements ]:
P280
[ Hazard Codes ]:
Xn
[ Risk Phrases ]:
R20/21/22
[ Safety Phrases ]:
S36/S37
[ RIDADR ]:
NONH for all modes of transport
[ RTECS ]:
TY1570210
Synthetic Route
Precursor & DownStream
Precursor
DownStream
Articles
Thromb. Haemost. 113(2) , 350-62, (2015)
Levosimendan is a positive inotropic drug for the treatment of acute decompensated heart failure (HF). Clinical trials showed that levosimendan was particularly effective in HF due to myocardial infar...
Effect of levosimendan on the contractility of muscle fibers from nemaline myopathy patients with mutations in the nebulin gene.Skelet. Muscle 5 , 12, (2015)
Nemaline myopathy (NM), the most common non-dystrophic congenital myopathy, is characterized by generalized skeletal muscle weakness, often from birth. To date, no therapy exists that enhances the con...
A Bayesian network meta-analysis on the effect of inodilatory agents on mortality.Br. J. Anaesth. 114 , 746-56, (2015)
Inodilators are commonly used in critically ill patients, but their effect on survival has not been properly studied to date. The objective of this work was to conduct a network meta-analysis on the e...